Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas.

Zhao, Cathy Yunjia; Fernández-Peñas, Pablo

Zhao, Cathy Yunjia; Fernández-Peñas, Pablo.

Affiliation

Zhao CY; Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia.
Fernández-Peñas P; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Australas J Dermatol ; 59(4): e297-e298, 2018 Nov.

Article in En | MEDLINE | ID: mdl-29672833

Subject(s)

Adalimumab/therapeutic use; Hidradenitis Suppurativa/drug therapy; Melanoma/complications; Skin Neoplasms/complications; Adalimumab/adverse effects; Adult; Hidradenitis Suppurativa/complications; Hidradenitis Suppurativa/diagnosis; Humans; Male; Melanoma/diagnosis; Middle Aged; Patient Safety; Risk Assessment; Sampling Studies; Skin Neoplasms/diagnosis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Hidradenitis Suppurativa / Adalimumab / Melanoma Type of study: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Australas J Dermatol Year: 2018 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google